1015 Capital Partners’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
1015 Capital Partners's SMMT Position: Q3 2026 in Review
1015 Capital Partners sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 4 shares — an estimated $58 sold.
1015 Capital Partners first reported a position in SMMT in Q4 2025 and held it in 3 quarters. The position peaked at $190 in Q1 2026. 297 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- 1015 Capital Partners reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
- 1015 Capital Partners sold 4 Summit Therapeutics shares in Q3 2026, an estimated $58.
- 1015 Capital Partners first reported a position in Summit Therapeutics in Q4 2025 and held it in 3 quarters.
- 1015 Capital Partners's Summit Therapeutics position peaked at $190 in Q1 2026.
- 297 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on 1015 Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.